Related Experiment Video

Updated: Jun 20, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Hepatitis C therapy--the future looks bright

Sohail A Qureshi1, Humaira Qureshi, Anam Hameed

  • 1Department of Biological & Biomedical Sciences, The Aga Khan University Hospital, Stadium Road, Karachi 74800, Pakistan. sohail.qureshi@aku.edu

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|September 4, 2009
PubMed

Insights

New Hepatitis C virus (HCV) treatments are needed due to limited efficacy and side effects of current therapies. Small-molecule inhibitors show promise in clinical trials for treating HCV infections.

Area of Science:

  • Hepatology
  • Virology
  • Medicinal Chemistry

Background:

  • Hepatitis C virus (HCV) affects 170 million globally, posing significant health risks if untreated.
  • Current treatments (ribavirin and interferon-alpha) have limited efficacy and severe side effects.
  • There is a critical need for novel antiviral therapies targeting HCV replication.

Purpose of the Study:

  • To provide an overview of emerging small-molecule inhibitors for Hepatitis C virus (HCV) treatment.
  • To highlight compounds that have demonstrated promise in clinical trials.
  • To discuss potential new therapies for HCV infections.

Main Methods:

  • Structure-based drug design approaches were utilized.
  • High-throughput screening methods were employed for compound identification.
  • Clinical trial data for promising small-molecule inhibitors were reviewed.

Main Results:

  • Several pharmaceutical companies have identified potentially effective compounds.
  • Small-molecule inhibitors have shown promise in ongoing clinical trials.
  • New HCV therapies may become available within three years.

Conclusions:

  • Small-molecule inhibitors represent a promising new class of drugs for HCV treatment.
  • Advancements in drug design and screening have accelerated the discovery process.
  • The pipeline of novel HCV therapeutics is robust, offering hope for improved patient outcomes.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...